BCT — Briacell Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$26.93m
- CA$19.46m
Annual income statement for Briacell Therapeutics, fiscal year end - July 31st, USD millions except per share, conversion factor applied.
2020 July 31st | R2021 July 31st | 2022 July 31st | 2023 July 31st | 2024 July 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | USG | USG | USG | USG |
| Status: | fx Final | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 3.58 | 7.11 | 15.3 | 23.3 | 33.3 |
| Operating Profit | -3.58 | -7.11 | -15.3 | -23.3 | -33.3 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -3.67 | -13.8 | -26.8 | -20.3 | -4.93 |
| Net Income After Taxes | -3.67 | -13.8 | -26.8 | -20.3 | -4.93 |
| Minority Interest | |||||
| Net Income Before Extraordinary Items | |||||
| Net Income | -3.67 | -13.8 | -26.8 | -20.3 | -4.79 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -3.67 | -13.8 | -26.8 | -20.3 | -4.79 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -77.7 | -45.4 | -26 | -19.5 | -4.37 |